CompletedPhase 2

Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis

China118 participantsStarted 2025-04-28

Plain-language summary

A multicenter, randomized, double-blind, vehicle controlled phase II clinical study

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF);
✓. The age requirement for signing the ICF is 18 years old or above, with no gender restrictions;
✓. During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria;

✕. Skin damage or abnormalities that may affect the evaluation of the administration site of the investigational drug;
✕. Skin diseases that are contraindicated in research or affect the evaluation of drug administration sites, including but not limited to psoriasis, acne, and skin cancer;
✕. Suffering from autoimmune diseases other than AD, such as inflammatory bowel disease and rheumatoid arthritis, and the researchers believe that this disease will be detrimental to the evaluation of this study;
✕. Current history of or presence of lymphoproliferative disorders, or signs or symptoms suggesting possible lymphoproliferative disorders, including lymphadenopathy or splenomegaly;
✕. Various malignant tumors, or any history of malignant tumors within the past 5 years prior to screening (excluding completely resected cervical carcinoma in situ, non metastatic squamous cell carcinoma, basal cell carcinoma, or papillary thyroid carcinoma);

Changes in EASI（Eczema area and severity index） from baseline

Timeframe: 8 week

NCT IDNCT06891040

SponsorJiangsu vcare pharmaceutical technology co., LTD

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-10-31

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF);
✓. The age requirement for signing the ICF is 18 years old or above, with no gender restrictions;
✓. During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria;

✕. Skin damage or abnormalities that may affect the evaluation of the administration site of the investigational drug;
✕. Skin diseases that are contraindicated in research or affect the evaluation of drug administration sites, including but not limited to psoriasis, acne, and skin cancer;
✕. Suffering from autoimmune diseases other than AD, such as inflammatory bowel disease and rheumatoid arthritis, and the researchers believe that this disease will be detrimental to the evaluation of this study;
✕. Current history of or presence of lymphoproliferative disorders, or signs or symptoms suggesting possible lymphoproliferative disorders, including lymphadenopathy or splenomegaly;
✕. Various malignant tumors, or any history of malignant tumors within the past 5 years prior to screening (excluding completely resected cervical carcinoma in situ, non metastatic squamous cell carcinoma, basal cell carcinoma, or papillary thyroid carcinoma);